303
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

Evaluation of the SIGNIFY trial

Evaluation of Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091-1099.

Pages 1861-1864 | Published online: 08 Jul 2015
 

Abstract

A reduction in the heart rate has been thought to be beneficial in coronary artery disease. The study assessing the morbidity–mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. It specifically evaluated the effects of ivabradine, administered at the dosage of 5 – 10 mg/bid in addition to current drug treatment, on cardiovascular outcome in 19102 patients with heart rate ≥ 70 bpm in normal sinus rhythm and stable coronary artery disease without heart failure. The primary endpoint of the trial, whose follow-up averaged for 2.3 years, was a composite of death from cardiovascular causes or nonfatal myocardial infarction whereas the secondary endpoint was represented by the primary endpoint plus total mortality. The incidence of the primary endpoint was at the study end similar in the ivabradine-treated and in the placebo-treated group (6.8 vs 6.4%, p = NS). Superimposable was also the incidence of death for cardiovascular events and for nonfatal myocardial infarction. However, in the 12049 patients with angina class II or higher ivabradine significantly increased the incidence of primary endpoint as compared to placebo (7.6 vs 6.5%, p < 0.02). This was associated with a significantly greater incidence of bradycardia, atrial fibrillation and Q-T prolongation. Taken together the results of the SIGNIFY do not support the clinical benefits of ivabradine in patients with stable coronary artery disease.

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.